Curation XLID SOX3

Gene SOX3
Disease XLID, PHPX
Inheritance XR
Score

3 + 2 = 5 / 18

Genetic + experimental = total
Classification
0
18
Refuted
Moderate
Definitive
Last Updated 05/14/2026
Pubs Reviewed 4
Publication Span 0.88 years
Publication Interval 0.88 years
Curator(s) Laurel Hiatt, Macayla Weiner, Harriet Dashnow
Description

Patients have been reported with SOX3 polyalanine repeat mutations associated with X-linked pituitary hormone deficiency with or without intellectual disability, with functional studies showing altered transactivation, protein aggregation in overexpression systems, and reduced SOX3 protein levels in a mouse expansion model. 5 total patients across 2 papers and a mouse model. SOX3 has previously been curated by the ClinGen Syndromic Disorders GCEP (08/02/2023) for SOX3-related X-linked pituitary hormone deficiency with or without intellectual developmental disorder.

Genetic evidence

Total: 3

Category
Type
Citation
Score
Details
Singular Evidence
Probands
1.5

One male proband with molecularly confirmed Kabuki syndrome and CPHD carried a hemizygous 21-bp SOX3 polyalanine-tract deletion (p.Ala239_245del7A); the SOX3 deletion was maternally inherited, while a separate MLL2 variant was de novo.

Collective Evidence
Segregation
1.5

One family with three affected males carrying a 21-bp in-frame SOX3 polyalanine expansion (+7 alanines) segregating with GH deficiency through carrier females; LOD = 2.68 and the expansion was absent from 100 control females.

Experimental evidence

Total: 2

Category
Type
Citation
Score
Details
Function
Regulatory impact
0.5

SOX3 polyalanine expansion mutants showed impaired transcriptional activation and reduced repression of β-catenin/TCF-mediated transcription in reporter assays.

Function
Biochemical function
0.5

SOX3 +7 and +11 alanine expansion proteins formed cytoplasmic and nuclear aggregates, including aggresome-like perinuclear aggregates, in transfected cell systems and chick neural explants.

Models
Non-human model organism
1

Sox3-26ala mouse/ES-cell model showed markedly reduced nuclear SOX3 protein, pituitary-region developmental abnormalities, no detectable in vivo aggregates, and a partial loss-of-function mechanism.

Maximum score caps apply at evidence type, category, and supercategory levels, so section totals may be lower than the raw sum of row scores.